APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

New Ruipeng Pet Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/new-ruipeng-pet-group-inc" target="_blank" data-smartkarma-citation="entities:36735:1" rel="noopener">New Ruipeng Pet Group (RPET US)</a> is looking to raise at least US$100m in its upcoming US IPO. </li>
<li>New Ruipeng Pet Group (Ruipeng) is a pet services platform, primarily offering pet care services, supply chain services and local services, covering the entire lifecycle of pets.</li>
<li>In this note, we will talk about the not-so-positive aspects of the deal.</li>
</ul>



New Ruipeng Pet Group (RPET US) is looking to raise at least US$100m in its upcoming US IPO. 
New Ruipeng Pet Group (Ruipeng) is a pet services platform, primarily offering pet care services, supply chain services and local services, covering the entire lifecycle of pets.
In this note, we will talk about the not-so-positive aspects of the deal.


New Ruipeng Pet Group Pre-IPO - The Negative - Loss-Making and Cash Burn Could Dampen Ambitions

<ul>
<li>
<a href="https://www.smartkarma.com/entities/new-ruipeng-pet-group-inc" target="_blank" data-smartkarma-citation="entities:36735:1" rel="noopener">New Ruipeng Pet Group (RPET US)</a> is looking to raise at least US$100m in its upcoming US IPO. </li>
<li>New Ruipeng Pet Group (Ruipeng) is a pet services platform, primarily offering pet care services, supply chain services and local services, covering the entire lifecycle of pets.</li>
<li>In this note, we will talk about the positive aspects of the deal.</li>
</ul>



New Ruipeng Pet Group (RPET US) is looking to raise at least US$100m in its upcoming US IPO. 
New Ruipeng Pet Group (Ruipeng) is a pet services platform, primarily offering pet care services, supply chain services and local services, covering the entire lifecycle of pets.
In this note, we will talk about the positive aspects of the deal.


New Ruipeng Pet Group Pre-IPO - The Positives - Compelling Growth Story Reflected in Sales Growth

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Becton Dickinson and Co / Equity Bottom-Up

<ul>
<li>Ruling on Ethylene Oxide in favor of Sotera is a positive for all the medical devices companies including <a href="https://www.smartkarma.com/entities/becton-dickinson-and-co" target="_blank" data-smartkarma-citation="entities:13061:1" rel="noopener">Becton Dickinson and Co (BDX US)</a>, who have EO sterilization facilities.  </li>
<li>In FY22, BD reported strong base business, which grew 6.9% y/y on reported basis. On currency-neutral basis, base business increased 9.4% y/y in FY22, accelerated from 8.1% in FY21.</li>
<li>FY22 marks 51st consecutive year of dividend increase for BD, which makes it one of the leading dividend yield stocks. Currently, the stock has a dividend yield of 1.53%.</li>
</ul>


Ruling on Ethylene Oxide in favor of Sotera is a positive for all the medical devices companies including Becton Dickinson and Co (BDX US), who have EO sterilization facilities.  
In FY22, BD reported strong base business, which grew 6.9% y/y on reported basis. On currency-neutral basis, base business increased 9.4% y/y in FY22, accelerated from 8.1% in FY21.
FY22 marks 51st consecutive year of dividend increase for BD, which makes it one of the leading dividend yield stocks. Currently, the stock has a dividend yield of 1.53%.


Becton Dickinson and Co (BDX US): EO Ruling Is Positive; Strong Base Business to Drive Growth Ahead

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher Scientific had a positive quarterly result as it surpassed Wall Street expectations on all counts and continued to drive market share gains.</li><li>Thermo Fisher strengthened its market position during this quarter as it advanced its industry-leading Thermo Scientific Orbitrap portfolio and launched the Orbitrap Ascend Tribrid mass spectrometer during the International Mass Spectrometry Conference.</li><li>We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.</li></ul>

Thermo Fisher Scientific had a positive quarterly result as it surpassed Wall Street expectations on all counts and continued to drive market share gains.Thermo Fisher strengthened its market position during this quarter as it advanced its industry-leading Thermo Scientific Orbitrap portfolio and launched the Orbitrap Ascend Tribrid mass spectrometer during the International Mass Spectrometry Conference.We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.

Thermo Fisher Scientific: New Technology For Cell Culture Harvesting & Other Drivers

<ul><li>Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust.</li><li>Excellent growth has been viewed over every business, highlighted by its pharma services and bioproduction businesses.</li><li>We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.</li></ul>

Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust.Excellent growth has been viewed over every business, highlighted by its pharma services and bioproduction businesses.We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.

Thermo Fisher Scientific: New Product Launches & Other Drivers

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals.  The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific Inc (TMO US)

New Ruipeng Pet Group Pre-IPO - The Negative - Loss-Making and Cash Burn Could Dampen Ambitions

New Ruipeng Pet Group (RPET US) is looking to raise at least US$100m in its upcoming US IPO. In this note, we will talk about the not-so-positive...

Clarence Chu

New Ruipeng Pet Group Pre-IPO - The Positives - Compelling Growth Story Reflected in Sales Growth

New Ruipeng Pet Group (RPET US) is looking to raise at least US$100m in its upcoming US IPO. Ruipeng is a pet services platform, primarily offering...

Clarence Chu

Becton Dickinson and Co (BDX US): EO Ruling Is Positive; Strong Base Business to Drive Growth Ahead

Recent EO ruling is positive for BD. Base business momentum, new launches targeting higher-impact and higher-growth markets, and tuck-in M&A should...

Tina Banerjee

Thermo Fisher Scientific: New Technology For Cell Culture Harvesting & Other Drivers

Thermo Fisher Scientific had a positive quarterly result as it surpassed Wall Street expectations on all counts and continued to drive market...

Baptista Research

Thermo Fisher Scientific: New Product Launches & Other Drivers

Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust. Excellent growth...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)